Drug Trial Radar · NCT04066478
Does DHEA IVF Outcomes in Poor Responders?
Last checked: Nov 20, 2026Latest source record: Jun 23, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Suspended
Enrollment
400
Planned (sponsor's estimate)
Start
Oct 8, 2017
Primary completion
Dec 31, 2022
Study completion Dec 31, 2022
Sponsor
- Lead sponsor
- Homerton University Hospital NHS Foundation TrustAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Aug 26, 2019
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Female only, from 40 years, up to 42 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is a RCT to examine whether DHEA is capable of improving results for poor responders to ovarian stimulation during IVF treatment
Conditions
- Infertility, Female
- Poor Response to Ovulation Induction
Interventions
DehydroepiandrosteroneDrug
75mg Dehydroepiandrosterone daily
PlaceboDrug
Placebo
Primary outcomes
What the sponsor says the trial is designed to measure.
- Clinical pregnancy ratesTime frame: at 6-8 weeks gestation
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Homerton Fertility Centre
London, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.